ProCE Banner Activity

A Clinician’s Guide to Selective RET Inhibitors for Patients With RET-Altered Lung and Thyroid Cancers: Indications, Dosing, and Adverse Events

PDF
Download this short PDF resource summarizing approved indications, dosing, and key safety data for the selective RET inhibitors pralsetinib and selpercatinib, including guidance on monitoring for and managing adverse events.

Released: January 21, 2021

Expiration: January 20, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly